

Table I. Effect of meningococcal vaccines on mucosal carriage. As compared to the polysaccharide counterparts, will conjugated MC vaccines more effectively reduce nasopharyngeal carriage of <i>N. meningitidis</i> and induce herd protection against meningococcal disease?				
			Rating	Adjustment to level
Quality Assessment	No of Studies/Starting quality starting level		4 observational studies	2
	Factors decreasing confidence	Limitation in study design	None serious	0
		Inconsistency	None serious	0
		Indirectness	None serious	0
		Imprecision	None serious	0
		Publication bias	None serious	0
	Factors increasing confidence	Large effect	Not applicable	0
		Dose-response	Not applicable	0
		Mitigated bias and confounding	Not applicable	0
	Final rating of quality of evidence			2
Summary of Findings	Statement on quality of evidence			Our confidence in the estimate of the effect on the health outcome is limited
	Conclusion			Conjugated MC vaccines reduce nasopharyngeal carriage of <i>N. meningitidis</i> and induce herd protection against meningococcal disease more effectively than do the corresponding polysaccharide vaccines

**Review of Observational Studies:** In 1988 *Hassan-King et al* conducted a study on Group A meningococcal carriage rates in a rural area of The Gambia. Carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%). The carriage rate remained high during a second survey made 6 months after the campaign that covered approximately 90% of the study population. A year later very few group A meningococcal carriers were found. It was concluded that vaccination had little influence on the carriage rate of group A meningococci but that this was influenced by changes in herd immunity or by other unidentified factors.

In 1999 *Maiden et al* conducted carriage studies on group C meningococci in 14,000 students aged 15-17 years. The surveys were conducted during and after meningococcal group C conjugate vaccine introduction. Carriage was reduced by 66%. Subsequently, Maiden et al conducted another cross-sectional surveys of meningococcal carriage in over 16000 students of the same age group attending school or college. A reduction in serogroup C carriage (rate ratio, 0.19) was observed that lasted at least 2 years with no evidence of serogroup replacement. Vaccine efficacy against carriage was 75%. The impact of vaccination with MCC vaccine on the prevalence of carriage of group C meningococci was consistent with herd immunity. High vaccine efficacy against disease in young children, who were not protected long-term by the schedule initially used, is attributed to the high vaccine efficacy against carriage in older age groups.

In 2007, *Dellicour S et al.* published a systematic review on the impact of meningococcal vaccination on pharyngeal carriage of meningococci. Of the 29 studies that satisfied the inclusion criteria. 25/29 reported the effect of a polysaccharide vaccine, 1/29 the effect of a serogroup C conjugate vaccine and 3/29 the impact of serogroup B outer-membrane vaccines on overall and/or serogroup-specific meningococcal carriage rates. Ten studies of meningococcal polysaccharide vaccines found reduced serogroup-specific carriage; seven of these focussed on high-risk groups and had a short follow-up period. Only one of five studies of civilian populations in Africa showed a significantly reduced carriage. Many studies had methodological shortcomings. The one study which assessed the effect of a meningococcal conjugate vaccine on carriage showed a significant impact. Three studies of serogroup B outer-membrane protein vaccines showed no effect on carriage.

## References:

- 1.Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. *J Infect.* 1988 Jan;16(1):55-9.
- 2.Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. *Lancet.* 2002 May 25;359(9320):1829-31.
- 3.Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. *J Infect Dis.* 2008 Mar 1;197(5):737-43.
- 4.Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. *Trop Med Int Health.* 2007 Dec;12(12):1409-21.